{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:38:56Z","timestamp":1792773536493,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"DOI":"10.1007\/s40744-026-00875-w","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:26:49Z","timestamp":1792769209000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bimekizumab in Chinese Patients with Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results from the Phase\u00a03 BE\u00a0MOBILE\u00a01 Study"],"prefix":"10.1007","clinical-trial-number":[{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jieruo","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangjing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengqian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Marten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marga","family":"Oortgiesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Vaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huji","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"Suppl 3","key":"875_CR1","volume":"27","author":"J Gu","year":"2024","unstructured":"Gu J, Lu L, Wang Q, et al. Bimekizumab in patients from China with active non-radiographic axial spondyloarthritis: 52-week results from BE\u00a0MOBILE\u00a01. Int J Rheum Dis. 2024;27(Suppl 3):e15346.","journal-title":"Int J Rheum Dis"},{"issue":"10473","key":"875_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0140-6736(24)02263-3","volume":"405","author":"V Navarro-Comp\u00e1n","year":"2025","unstructured":"Navarro-Comp\u00e1n V, Sepriano A, Capelusnik D, et al. Axial spondyloarthritis. Lancet. 2025;405(10473):159\u201372.","journal-title":"Lancet"},{"issue":"8","key":"875_CR3","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1093\/rheumatology\/keab901","volume":"61","author":"D Poddubnyy","year":"2021","unstructured":"Poddubnyy D, Sieper J, Akar S, et al. Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results. Rheumatology (Oxford). 2021;61(8):3299\u2013308.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"875_CR4","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599\u2013613.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"875_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01387-x","volume":"28","author":"SX Huang","year":"2023","unstructured":"Huang SX, Li HG, Liang HJ, et al. Comparison of clinical characteristics between adult-onset and juvenile-onset non-radiographic axial spondyloarthritis in Chinese patients: results from the COCAS cohort. Eur J Med Res. 2023;28(1):388.","journal-title":"Eur J Med Res"},{"issue":"3","key":"875_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001752","volume":"7","author":"M Kishimoto","year":"2021","unstructured":"Kishimoto M, Ono K, Fukui S, et al. Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study. RMD Open. 2021;7(3):e001752.","journal-title":"RMD Open"},{"key":"875_CR7","unstructured":"Chinese Rheumatology Association; Committee for Rheumatologists and Immunologists of Chinese Primary Health Care Foundation. Guideline for the diagnosis and treatment of non-radiographic axial spondyloarthritis (2024 edition). Zhonghua Yi Xue Za Zhi. 2025;105(13):981\u20131003."},{"issue":"21","key":"875_CR8","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1097\/CM9.0000000000002047","volume":"135","author":"Y Sun","year":"2022","unstructured":"Sun Y, Wang J, Qiu Y, et al. Real-life effectiveness and safety of secukinumab in axial spondyloarthritis: a single-center study. Chin Med J (Engl). 2022;135(21):2623\u20134.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"875_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40259-023-00625-2","volume":"38","author":"Y Xue","year":"2024","unstructured":"Xue Y, Hu J, Liu D, et al. Ixekizumab for active radiographic axial spondyloarthritis in Chinese patients: 16- and 52-week results from a phase III, randomized, double-blind, placebo-controlled study. BioDrugs. 2024;38(1):145\u201356.","journal-title":"BioDrugs"},{"issue":"4","key":"875_CR10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s40744-024-00688-9","volume":"11","author":"X Zhu","year":"2024","unstructured":"Zhu X, Hu J, Liu D, et al. Rapid and sustained effect of ixekizumab on patient global, spinal pain, stiffness, and fatigue in Chinese patients with radiographic axial spondyloarthritis. Rheumatol Ther. 2024;11(4):1011\u201322.","journal-title":"Rheumatol Ther"},{"issue":"Suppl 2","key":"875_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/annrheumdis-2017-eular.3846","volume":"76","author":"M Zhao","year":"2017","unstructured":"Zhao M, Shi G, Tao Y, et al. THU0384\u2005The effect and safety of yisaipu (YISAIPU) in the treatment of patients with nonradiographic axial spondyloarthritis in China. Ann Rheum Dis. 2017;76(Suppl 2):351\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"875_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","volume":"77","author":"S Glatt","year":"2018","unstructured":"Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"875_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001306","volume":"6","author":"M Shah","year":"2020","unstructured":"Shah M, Maroof A, Gikas P, et al. Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open. 2020;6(2):e001306.","journal-title":"RMD Open"},{"issue":"2","key":"875_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/ard-2023-224803","volume":"83","author":"X Baraliakos","year":"2024","unstructured":"Baraliakos X, Deodhar A, van der Heijde D, et al. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE\u00a0MOBILE\u00a01 and BE\u00a0MOBILE 2 studies. Ann Rheum Dis. 2024;83(2):199\u2013213.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"875_CR15","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1093\/rheumatology\/keaf009","volume":"64","author":"X Baraliakos","year":"2025","unstructured":"Baraliakos X, Deodhar A, van der Heijde D, et al. Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies. Rheumatology (Oxford). 2025;64(6):3534\u201346.","journal-title":"Rheumatology (Oxford)"},{"key":"875_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/ard-2022-223595","volume":"82","author":"D van der Heijde","year":"2023","unstructured":"van der Heijde D, Deodhar A, Baraliakos X, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis. 2023;82:515\u201326.","journal-title":"Ann Rheum Dis"},{"key":"875_CR17","doi-asserted-by":"publisher","unstructured":"Gu J, Lu L, Wang Q, et al. Bimekizumab in Chinese patients with active radiographic axial spondyloarthritis: 52-week results from the phase 3 BE MOBILE 2 Study. Chin Med J (Engl). 2026. https:\/\/doi.org\/10.1097\/CM9.0000000000004237 (in press).","DOI":"10.1097\/CM9.0000000000004237"},{"key":"875_CR18","unstructured":"National Medical Products Administration. 2024. https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20240719151602155.html. Accessed Jan 2025."},{"issue":"12","key":"875_CR19","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.38140","volume":"65","author":"A Ciurea","year":"2013","unstructured":"Ciurea A, Scherer A, Exer P, et al. Tumor necrosis factor \u03b1 inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum. 2013;65(12):3096\u2013106.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"875_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/art.24483","volume":"60","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondylarthritis: results from the German spondyloarthritis inception cohort. Arthritis Rheum. 2009;60(3):717\u201327.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"875_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13075-021-02613-9","volume":"23","author":"J Braun","year":"2021","unstructured":"Braun J, Blanco R, Marzo-Ortega H, et al. Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. Arthritis Res Ther. 2021;23(1):231.","journal-title":"Arthritis Res Ther"},{"key":"875_CR22","unstructured":"Magrey M, Marzo-Ortega H, Kadono Y, et al. Bimekizumab was efficacious regardless of age, BMI, CRP, or HLA-B27 status: 1-year results from two phase 3 studies [abstract]. Arthritis Rheumatol. 2025;77(Suppl 9). https:\/\/acrabstracts.org\/abstract\/bimekizumab-was-efficacious-regardless-of-age-bmi-crp-or-hla-b27-status-1-year-results-from-two-phase-3-studies\/. Accessed\u00a0Mar 2026."},{"issue":"1","key":"875_CR23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.41477","volume":"73","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Blanco R, Dokoupilov\u00e1 E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 2021;73(1):110\u201320.","journal-title":"Arthritis Rheumatol"},{"key":"875_CR24","doi-asserted-by":"publisher","unstructured":"Cundiff-O\u2019Sullivan RL, Oula D, Shafir R, et al. Cultural influences on placebo and nocebo effects. 2023. In: Placebo effects through the lens of translational research [Internet]. Oxford University Press. p. 38\u201354. https:\/\/doi.org\/10.1093\/med\/9780197645444.003.0004. Accessed May 2025.","DOI":"10.1093\/med\/9780197645444.003.0004"},{"issue":"7","key":"875_CR25","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/1756-185X.13853","volume":"23","author":"A Chopra","year":"2020","unstructured":"Chopra A, Shobha V, Chandrashekara S, et al. Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: a post hoc analysis of efficacy and safety in phase 3 and long-term extension studies over 7 years. Int J Rheum Dis. 2020;23(7):882\u201397.","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"875_CR26","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40744-024-00677-y","volume":"11","author":"GC Wright","year":"2024","unstructured":"Wright GC, Mysler E, Kwok K, et al. Impact of race on the efficacy and safety of tofacitinib in rheumatoid arthritis: post hoc analysis of pooled clinical trials. Rheumatol Ther. 2024;11(5):1135\u201364.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"875_CR27","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/mi.2017.97","volume":"11","author":"J Li","year":"2018","unstructured":"Li J, Casanova JL, Puel A. Mucocutaneous IL-17 immunity in mice and humans: host defense vs. excessive inflammation. Mucosal Immunol. 2018;11(3):581\u20139.","journal-title":"Mucosal Immunol"},{"issue":"3","key":"875_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.15076","volume":"27","author":"H Cinakli","year":"2024","unstructured":"Cinakli H, Ediboglu ED, Solmaz D, et al. Factors associated with acute anterior uveitis history in patients with axial spondyloarthritis: results of a longitudinal study. Int J Rheum Dis. 2024;27(3):e15076.","journal-title":"Int J Rheum Dis"},{"issue":"12","key":"875_CR29","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1136\/ard-2024-225933","volume":"83","author":"MA Brown","year":"2024","unstructured":"Brown MA, Rudwaleit M, van Gaalen FA, et al. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b\/3 trials. Ann Rheum Dis. 2024;83(12):1722\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"875_CR30","doi-asserted-by":"publisher","first-page":"544","DOI":"10.55563\/clinexprheumatol\/dybvei","volume":"40","author":"J Su","year":"2022","unstructured":"Su J, Wang R, Duan X, et al. Clinical characteristics of axial spondyloarthritis patients in China: results from ChinaSpA, the Chinese Spondyloarthritis Registry. Clin Exp Rheumatol. 2022;40(3):544\u201350.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"875_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph14030238","volume":"14","author":"X Li","year":"2017","unstructured":"Li X, Song P, Li J, et al. The disease burden and clinical characteristics of inflammatory bowel disease in the Chinese population: a systematic review and meta-analysis. Int J Environ Res Public Health. 2017;14(3):238.","journal-title":"Int J Environ Res Public Health"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00875-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00875-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00875-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:26:50Z","timestamp":1792769210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00875-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":31,"alternative-id":["875"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00875-w","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jieruo Gu, Liangjing Lu, Qiang Wang, Xiaobing Wang, Yongjing Cheng, Shengqian Xu, Yi Zhao, Qi Zhu: Nothing to declare. Xenofon Baraliakos: Scientific advisory board for AbbVie, Advanz, Alexion, Alphasigma, Amgen, BMS, Cesas, Celltrion, Clarivate, Galapagos, J&J, Eli Lilly, MoonLake, Novartis, Peervoice, Pfizer, Roche, Sandoz, Springer, Stada, Takeda, UCB, and Zuellig; research grants from AbbVie, Celltrion, Janssen, MoonLake, and Novartis; non-commercial disclosures as ASAS Past President and EULAR President-Elect. Matthew A. Brown: Grant\/Research support from UCB; consultant for Altis Medicines, Clementia, Grey Wolf Therapeutics, Incyte, Ipsen, Regeneron, and Xinthera. Atul Deodhar: Speaker for Eli Lilly, J&J, Novartis, Pfizer, and UCB; consultant for BMS, Eli Lilly, J&J, MoonLake, Novartis, Pfizer, and UCB; grant\/research support from BMS, Eli Lilly, J&J, Novartis, Pfizer, and UCB. James Cheng-Chung Wei: Research grant, speaker fee or advisory board from Abbott, AbbVie, BMS, Celgene, Chugai, Eli Lilly, GSK, JNJ, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis, and UCB. Marga Oortgiesen, Tom Vaux: Employee and shareholder of UCB. Alexander Marten: Employee of UCB. Huji Xu: Speaker for AbbVie, Janssen, Novartis, Pfizer, and UCB; consultant for AbbVie, Beigene, BioMap, IASO, Pfizer, and UCB; clinical investigator for Peking-Tsinghua Centre for Life Sciences.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The BE\u00a0MOBILE\u00a01 study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Guidance for Good Clinical Practice. Ethical approvals were obtained from the relevant institutional review boards at participating sites. All patients provided written informed consent in accordance with local requirements. Participants gave informed consent to participate in the study before taking part.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}